Elon Musk's Starlink network suffers rare global outage
SpaceX's Starlink experienced one of its most significant global outages on Thursday due to an internal software malfunction that left tens of thousan...
A groundbreaking study presented at ASCO reveals that AstraZeneca’s experimental pill camizestrant, when used based on blood test results, can halve the risk of breast cancer progression or death—potentially reshaping treatment for patients with hormone receptor-positive, HER2-negative breast cancer
AstraZeneca’s experimental drug camizestrant significantly reduced the risk of disease progression or death in patients with advanced hormone receptor-positive, HER2-negative breast cancer by 56%, when prescribed based on early blood test results rather than visible tumor growth, experts announced Sunday at the American Society of Clinical Oncology (ASCO) meeting in Chicago.
The international trial marks a major shift in cancer treatment strategy by using liquid biopsy—a blood test that detects ESR1 gene mutations indicating early resistance to standard hormone therapies. Camizestrant, a selective estrogen receptor degrader (SERD), was shown to be effective in patients with early treatment resistance, even before tumors could be detected via imaging.
“This is going to be very impactful for our patients,” said Dr. Hope Rugo, head of breast medical oncology at City of Hope, California. “We’re staying ahead of the curve rather than reacting after the disease has already progressed,” added Dr. Eleonora Teplinsky, another ASCO expert.
The Phase 3 clinical trial involved 3,256 women, all previously treated with aromatase inhibitors and CDK4/6 inhibitors like Pfizer’s Ibrance or Novartis’ Kisqali. Among them, 315 women who developed ESR1 mutations were selected for a randomized trial. Those who switched to camizestrant plus CDK4/6 inhibitors experienced a median 16 months of progression-free survival compared to 9.2 months in the control group that continued standard therapy.
Camizestrant is not yet FDA-approved, but based on these findings, it may soon be adopted as part of a new treatment paradigm for early intervention in breast cancer progression.
AstraZeneca CEO Pascal Soriot acknowledged that integrating liquid biopsy into routine practice would initially be challenging but emphasized it as the future of cancer care.
In a separate announcement at the same ASCO meeting, another AstraZeneca drug, Imfinzi (durvalumab), showed promise in improving outcomes for early-stage stomach and esophageal cancer patients. When added to chemotherapy before and after surgery, Imfinzi reduced the risk of cancer recurrence, progression, or death by 29%.
Both sets of results were published in the New England Journal of Medicine and are expected to have lasting implications for the future of oncology.
The world’s biggest dance music festival faces an unexpected setback as a fire destroys its main stage, prompting a last-minute response from organisers determined to keep the party alive in Boom, Belgium.
Australian researchers have created a groundbreaking “biological AI” platform that could revolutionise drug discovery by rapidly evolving molecules within mammalian cells.
Australian researchers have pioneered a low-cost and scalable plasma-based method to produce ammonia gas directly from air, offering a green alternative to the traditional fossil fuel-dependent Haber-Bosch process.
A series of earthquakes have struck Guatemala on Tuesday afternoon, leading authorities to advise residents to evacuate from buildings as a precaution against possible aftershocks.
The U.S. economy faces a 40% risk of recession in the second half of 2025, JP Morgan analysts said on Wednesday, citing rising tariffs and stagflation concerns.
The World Health Organization (WHO) warned on Tuesday that the world could be on the brink of another chikungunya epidemic, similar to the 2005 outbreak, unless swift measures are implemented to control its spread.
Every Sunday evening at Chicago’s North Avenue Beach, the sound of collective shouting echoes across Lake Michigan – not from protestors, but from Scream Club Chicago, a group gathering to relieve stress by screaming into the open air.
A major study warns that antibiotic-resistant superbugs could kill millions each year while shrinking the global economy by almost $2 trillion annually by 2050, a crisis driven in part by international aid cuts that undermine resistance efforts.
The United States has rejected a global pandemic treaty adopted by the World Health Organization (WHO), saying it threatens national sovereignty and lacks clear language.
Ukrainian President Volodymyr Zelenskyy announced on Thursday that Deputy Prime Minister Olha Stefanishyna, who currently oversees European and Euro-Atlantic integration, has been appointed as Ukraine’s next ambassador to the United States.
You can download the AnewZ application from Play Store and the App Store.
What is your opinion on this topic?
Leave the first comment